More News! 1 Aug 2019 Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed as the UK company Atlantic Healthcare’s RNA drug has proved ineffective in a phase III trial. The trial tested Atlantic Healthcare’s RNA drug alicaforsen as a treatment for patients with pouchitis. Patients with this condition have their colon surgically replaced […] August 1, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2019 British Biotech Raises €11M to Market Personalized Medicine Test The UK biotech PredictImmune has raised €11M (£10M) in a Series B fundraising round to commercialize technology to predict the progress of inflammatory bowel disease in newly diagnosed patients. The funds will finance the global launch of PredictSURE IBD, a blood test that can identify patients with the most severe cases of inflammatory bowel disease, […] July 31, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2019 €43M Series C to Launch UK Company’s Home Hemodialysis Kit Quanta Dialysis Technologies has raised €43.2M ($48M) to fund the commercial launch of a device that makes home hemodialysis more straightforward and economical for kidney failure patients. The UK-based Quanta will use the money to launch its technology in the UK later this year, and also apply for FDA approval. The technology previously obtained a […] July 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 19 Jul 2019 Mallinckrodt Teams up with UK RNAi Biotech in Deal Worth up to €553M The UK-based biotech Silence Therapeutics has signed a deal worth up to €553M ($693M) with the UK pharma company Mallinckrodt to develop RNA interference (RNAi) therapies for autoimmune diseases. Mallinckrodt will pay Silence Therapeutics €17.8M ($20M) upfront, and up to €600M ($673M) in developmental milestone payments. In exchange, it will get a license for an […] July 19, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 19 Jul 2019 UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech The UK-based venture capital investment firm Medicxi has closed its third fund, totaling €400M, to nurture early- and late-stage healthcare biotech companies in Europe. The firm will begin investing in the first beneficiary companies of this fund in the next few months. The big round was raised in just six weeks, and dwarfs Medicxi’s previous […] July 19, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 3 Jul 2019 Meet the First Company in the Brand New Field of Epitranscriptomics A whole new therapeutic area is taking medical research by storm. In Cambridge, UK, the company Storm Therapeutics is leading the development of the first treatments to target a new layer of genetic information encoded in the RNA. The term ‘epitranscriptomics’ did not exist a decade ago. It was coined in 2012, when scientists started […] July 3, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 28 Jun 2019 This Biotech Makes Dyes from Agricultural Waste Using Microbes Welcome to Norwich, UK, where Colorifix converts agricultural waste products into dyes using microbes, reducing the water and energy required to produce the dyes. Mission: To make textile dyes more sustainable by replacing chemical methods with microbial fermentation. Dyes are an essential part of the textile and fashion industries. The majority of dyes today are […] June 28, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2019 This Biotech Transports Cell Therapies Without Needing a Freezer The biotech Atelerix, based in Newcastle, UK, can transport cell therapies between different locations with less cost and risk than current methods by encapsulating the cells in a specialized gel. Mission: To eliminate the need for costly cold storage in the cell transport process by preserving cells in a gel. This could save further costs […] June 21, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jun 2019 The 10 Biotech Companies in London to Keep an Eye on in 2019 Which biotechs will be stealing the show this year? These are some of the most exciting biotech companies in London right now. London is undoubtedly one of the biggest hubs for biotech companies in the U.K. and in Europe. The British capital was the one that received the most life sciences investment in Europe in […] June 10, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2019 UK Immune Cell Therapy Biotech Founded with €40M Series A Quell Therapeutics, a London-based biotech developing immune cell therapies to target transplant rejection and autoimmune and inflammatory diseases, launched today with €40M series A funding. UK life sciences trust Syncona is the lead investor, with a €38.8M stake in the company. Syncona will own a controlling 69% of the business, reflecting their large initial investment. […] May 20, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2019 Update: British RNA Biotech Increases Series A to €34M Update (20/05/19): Storm Therapeutics has increased its series A financing round by an additional €16M (£14M) to €34M (£30M), which the company plans to use to advance its pipeline of RNA focused drug candidates towards the clinic. Seroba Life Sciences, an Irish VC focusing on new and innovative therapies, is the key new investor. Existing […] May 20, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 16 May 2019 UK Scientists Open Bacterial Genome Up to Making Artificial Proteins A research group from the University of Cambridge has created bacteria with less complexity in their genome, which could free up DNA code for producing synthetic proteins never before seen in nature. There are lots of redundancies in the DNA code, meaning there is sometimes more than one DNA sequence that can result in the […] May 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email